



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/887,465	06/22/2001	Edward B. Nelson	MCP267

000027777
AUDLEY A. CIAMPORCERO JR.
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933-7003



CONFIRMATION NO. 6932

FORMALITIES LETTER



0000000006436352

Date Mailed: 08/16/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

09887465-02202

MAR 22 '02 15:56 FR [REDACTED] PATENT LAW

732 524 5889 TO [REDACTED] 37464060

P. 13/22
Page 2 of 2

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

20080220 59428360

MAR 22 '02 15:53 FR

PATENT LAW

732 524 5889 TO

37464060

P.01

0410
COPY OF PAPERS
ORIGINALLY FILED
01/28/02

Johnson & Johnson

**CORPORATE HEADQUARTERS
PATENT LAW DEPARTMENT
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NEW JERSEY 08933**



FACSIMILE TRANSMISSION COVER SHEET

TO: UNITED STATES PATENT & TRADEMARK OFFICE

COMPANY:

COUNTRY: U.S.A.

FACSIMILE NUMBER: 1-703-746-4060

FROM: Michele Mangini

TELEPHONE NO.: 732-524-2810

ROOM NO.: 3233

DATE: March 22, 2002

FACSIMILE NUMBER: 732-524-5889

NUMBER OF PAGES INCLUDING THIS COVER SHEET: 22

**IF THERE IS A PROBLEM WITH THIS TRANSMISSION, PLEASE CALL
732-524-2820**

COMMENTS:

THIS MESSAGE IS INTENDED ONLY FOR THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE SOLELY TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

54

Docket No. MCP-267

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Edward B. Nelson et al.
Serial No. : 09/887,465 Art Unit : 1614
Filed : June 22, 2001 Examiner :
Title : USE OF ACETAMINOPHEN TO
PREVENT AND TREAT ARTERIOSCLEROSIS



I hereby certify that this correspondence is being transmitted
via facsimile to the United States Patent Office at (703) 747-4060 on:

March 22, 2002
(Date of Deposit)

Michela G. Mangini
(Name of applicant, assignee, or Registered Representative)

Michela G. Mangini
(Signature)

March 22, 2002
(Date of Signature)

Honorable Commissioner of Patents
Washington, D.C. 20231

LETTER

Dear Sir:

This letter is responsive to the Request for Substitute Papers mailed 15 March 2002 in the above-reference application (copy attached).

Attached herewith is a copy of the papers filed 1/28/02 (certificate of mailing dated 10/23/01). Applicants respectfully submit that these copies are complete and accurate copies of these papers.

Respectfully submitted,
Nelson et al.

By: *Michela G. Mangini*
Michela G. Mangini
Attorney for Applicants
Reg. No. 36,806

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2810
Dated: March 22, 2002

09887465-022302

DOCKET NO. MCP-267
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Edward B. Nelson et al.

Serial No.: 09/887,465

Art Unit: 1614

Filed : June 22, 2001

Examiner:

For : USE OF ACETAMINOPHEN TO PREVENT AND TREAT ARTERIOSCLEROSIS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Missing Parts, Commissioner for Patents, Washington, DC 20231 on

October 23, 2001

(Date of Deposit)

Michele G. Mangini

(Name of applicant, assignee, or Registered Representative)

October 23, 2001

(Date of Signature)



BOX MISSING PARTS
Commissioner for Patents
Washington, D.C. 20231

SUBMISSION OF COMBINED DECLARATION AND POWER OF ATTORNEY

Dear Sir:

Pursuant to Rule 53(f) and Rule 54, please find enclosed a Combined Declaration and Power of Attorney for the application of Edward B. Nelson et al. entitled "USE OF ACETAMINOPHEN TO PREVENT AND TREAT ARTERIOSCLEROSIS" attorney Docket No. MCP-267, to complete, pursuant to Rule 51, this application filed on June 22, 2001 by Express Mail pursuant to Rule 10. As required, a copy of the Notice to File Missing Parts of Application is also attached.

Also attached herewith is a copy of Submission of Formal Drawings and drawing attached thereto which are concurrently being mailed to the Official Draftsman.

Please charge Johnson & Johnson Deposit Account No. 10-0750/MCP-267/MGM in the amounts of \$130.00 for submission of the Declaration pursuant to Section 1.16(e). The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 10-0750/MCP-267/MGM. This sheet is submitted in triplicate.

Respectfully submitted,

Michele G. Mangini

Reg. No. 36,806

Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2810



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20331
www.uspto.gov

Application Number	Filing Date	First Named Applicant	Atty. Docket No.
09/887,465	06/22/2001	Nelson, Edward	MCP-267

27777

AUDLEY A. CIAMPORCERO JR.
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK NJ 08933-7003



Title: Use of acetaminophen to prevent and treat arteriosclerosis

Date Mailed: 03/15/2002

Request for Substitute Papers

The papers filed on 01/28/02 (certificate of mailing dated 10/23/01) are no longer in condition to become part of the permanent records of the United States Patent and Trademark Office (USPTO) for this application (37 CFR 1.52(a)) due to the United States Postal Service sanitization process.

The USPTO requests that applicant provide a copy of the above-identified papers (except for any U.S. or foreign patent documents submitted with the above-identified papers) with a statement that such copy is a complete and accurate copy of the above-identified papers (signing and returning a copy of this notice will provide such a statement). The reply to this letter should be submitted to the USPTO by facsimile at the number indicated **703-746-4060(OIPE)**.

Alternatively, the reply to this letter may be hand-carried to the Customer Service Window located in Room 1B03 of Crystal Plaza Building 2, Arlington, Virginia, 22202.

The USPTO **strongly** prefers that the reply to this letter be submitted by facsimile. However, if applicant cannot submit the reply to this letter by facsimile (or hand-delivery), the reply may be mailed to: Box Duplicate OIPE, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202-2327.

This letter is not a notice under 37 CFR 1.251. However, failure to timely replay to this notice within **two (2) weeks** of the date of receipt of this letter may result in the USPTO issuing a notice under 37 CFR 1.251. A copy of this notice should be included with the reply.

The enclosed papers are a complete and accurate copy of the above-identified papers.

Name: Michael Mangia Registration No.: 36,806

Signature: Michele Mangia Date: 3/22/02

RECEIVED

MAR 20 2002

J & J PAT. DKT. SECTION

DOCKET NO. MCP-267

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Edward B. Nelson et al.

Serial No.: 09/887,465

Art Unit: 1614

Filed : June 22, 2001

For : USE OF ACETAMINOPHEN TO PREVENT
AND TREAT ARTERIOSCLEROSIS


I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner for Patents, Washington, D.C. 20231 on

October 23, 2001

(Date of Deposit)

Michele G. Mangini

Name of applicant, assignee, or Registered Representative



(Signature)

October 23, 2001

(Date of Signature)



Commissioner for Patents
Washington, D.C. 20231


SUBMISSION OF FORMAL DRAWINGS (PHOTOCOPIES)Attention: Official Draftsman

Sir:

Applicants herewith submit one set of photocopies of one (1) sheet of
formal drawings in connection with the above-identified patent application.

Please charge any fees which may be required for this submission to
Johnson & Johnson Deposit Account No. 10-0750/MCP-267/MGM. Three copies of this
sheet are enclosed.

Respectfully submitted,


Michele G. Mangini
Attorney for Applicants
Reg. No. 36,806

Johnson & Johnson
One John on & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2810



SERIAL NO. 09/387,465 DOCKET NO. MCP-267 BY MM/rb
APPLICATION OF Edward B. Nelson et al. MAILED: 10/23/01
ENTITLED USE OF ACETAMINOPHEN TO PREVENT AND TREAT ...

THE FOLLOWING HAS BEEN RECEIVED IN THE U.S. PATENT OFFICE ON THE DATE
STAMPED HEREON:

<input type="checkbox"/> AFFIDAVIT	<input type="checkbox"/> DECLARATION	<input checked="" type="checkbox"/> EXTENSION OF TIME <u>(1 month)</u>
<input type="checkbox"/> AMENDMENT		<input type="checkbox"/> NOTICE OF APPEAL
<input type="checkbox"/> ASSIGNMENT FOR RECORDING		<input checked="" type="checkbox"/> OATH OR <input checked="" type="checkbox"/> DECLARATION
<input type="checkbox"/> BRIEF		<input checked="" type="checkbox"/> POWER OF ATTORNEY
<input checked="" type="checkbox"/> CHARGE TO DEPOSIT ACCOUNT 10-0750		<input type="checkbox"/> PRELIMINARY STATEMENT
<input checked="" type="checkbox"/> DRAWINGS <u>Fig. 1 (1 sheet - Frml)</u>		<input type="checkbox"/> PRIORITY DOCUMENT
<input type="checkbox"/> ISSUE FEE TRANSMITTAL		<input type="checkbox"/> STATUS INQUIRY
<input checked="" type="checkbox"/> LETTER (Submission of Declaration		<input type="checkbox"/> SPECIFICATION <u> </u> PGS
<input type="checkbox"/> PCT FILING & Power of Atty)		<input type="checkbox"/> CLAIMS <u> </u>
<input type="checkbox"/> IDS - FORM-1449		<input checked="" type="checkbox"/> <u>Cert. of Mailing</u>

FORM 113724 REV. 7/06